Tigecycline accelerates staphylococcal-infected burn wound healing through matrix metalloproteinase-9 modulation

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 191-201

  Simonetti, Oriana ^a   Cirioni, Oscar ^a   Lucarini, Guendalina ^a   Orlando, Fiorenza ^b   Ghiselli, Roberto ^a   Silvestri, Carmela ^a   Brescini, Lucia ^a   Rocchi, Marco ^c   Provinciali, Mauro ^b   Guerrieri, Mario ^a   Di Primio, Roberto ^a   Giacometti, Andrea ^a   Offidani, Annamaria ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c UNIVERSITY OF URBINO   (Italy)

Author keywords

Animal models; Methicillin resistant staphylococcus aureus; MMP 9; Teicoplanin

Indexed keywords

COLLAGEN TYPE 4; GELATINASE B; TEICOPLANIN; TIGECYCLINE; DRUG DERIVATIVE; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BURN; BURN INFECTION; BURN PATIENT; CONTROLLED STUDY; DEBRIDEMENT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RAT; WOUND HEALING; ANIMAL; BACTERIAL LOAD; CYTOCHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; PATHOGENICITY; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; WISTAR RAT; WOUND INFECTION;

ANIMALS; BACTERIAL LOAD; BURNS; DISEASE MODELS, ANIMAL; HISTOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 9; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MINOCYCLINE; RATS; RATS, WISTAR; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; TREATMENT OUTCOME; WOUND HEALING; WOUND INFECTION;

EID: 84859168557     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr440     Document Type: Article

References (60)

1. Cook N. Methicillin-resistant Staphylococcus aureus versus the burn patient. Burns 1998; 24: 91-8.
2. Elsner P. Antimicrobials and the skin physiological and pathological flora. Curr Probl Dermatol 2006; 33: 35-41.
3. Guggenheim M, Zbinden R, Handschin AE et al. Changes in bacterial isolates from burn wounds and their antibiograms: a 20-year study (1986-2005). Burns 2009; 35: 553-60.
4. Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. J Hosp Infect 2008; 70: 3-10.
5. Altoparlak U, Erol S, Akcay MN et al. The time-related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns 2004; 30: 660-4.
6. Appelgren P, Bjornhagen V, Bragderyd K et al. A prospective study of infections in burn patients. Burns 2002; 28: 39-46.
7. de Macedo JL, Rosa SC, Castro C. Sepsis in burned patients. Rev Soc Bras Med Trop 2003; 36: 647-52.
8. Santucci SG, Gobara S, Santos CR et al. Infections in a burn intensive care unit: experience of seven years. J Hosp Infect 2003; 53: 6-13.
9. Phillips LG, Heggers JP, Robson MC. Burn and trauma units as sources of methicillin-resistant Staphylococcus aureus. J Burn Care Rehabil 1992; 13: 293-7.
10. Enright MC. The evolution of a resistant pathogen-the case of MRSA. Curr Opin Pharmacol 2003; 3: 474-9.
11. Metzger R, Bonatti H, Sawyer R. Future trends in the treatment of serious Gram-positive infections. Drugs Today 2009; 45: 33-45.
12. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
13. Bouza E. New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2009 15: 44-52.
14. Erol S, Altoparlak U, Akcay MN et al. Changes of microbial flora and wound colonization in burned patients. Burns 2004; 30: 357-61.
15. Steenbergen JN, Alder J, Thorne GM et al. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005; 55: 283-8.
16. Peterson LR. A review of tigecycline-the first glycylcycline. Int J Antimicrob Agents 2008; 32 Suppl 4: S215-22.
17. Steenbergen JN, Mohr JF, Thorne GM. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 2009; 64: 1130-8.
18. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7: 728-35.
19. Parks WC. Matrix metalloproteinases in repair. Wound Repair Regen 1999; 7: 423-32.
20. Seltzer JL, Weingarten H, Akers KT et al. Cleavage specificity of type IV collagenase (gelatinase) from human skin. Use of synthetic peptides as model substrates. J Biol Chem 1989; 264: 19583-6.
21. Ries C, Popp T, Egea V et al. Matrix metalloproteinase-9 expression and release from skin fibroblasts interacting with keratinocytes: upregulation in response to sulphur mustard. Toxicology 2009; 263: 26-31.
22. Han YP, Nien YD, Garner WL. Tumor necrosis factor-a-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase. J Biol Chem 2002; 277: 27319-27.
23. Salo T, Makela M, Kylmaniemi M et al. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest 1994; 70: 176-82.
24. Young PK, Grinnell F. Metalloproteinase activation cascade after burn injury: a longitudinal analysis of the human wound environment. J Invest Dermatol 1994; 103: 660-4.
25. Tarlton JF, Vickery CJ, Leaper DJ et al. Postsurgical wound progression monitored by temporal changes in the expression of matrix metalloproteinase-9. Br J Dermatol 1997; 137: 506-16.
26. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101: 64-8.
27. Ladwig GP, Robson MC, Liu R et al. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen 2002; 10: 26-37.
28. Agren MS, Mirastschijski U, Karlsmark T et al. Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds. Exp Dermatol 2001; 10: 337-48.
29. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat Rev Mol Cell Biol 2007; 8: 221-33.
30. Bjellerup M. Novel method for training skin flap surgery: polyurethane foam dressing used as a skin equivalent. Dermatol Surg 2005; 31: 1107-11.
31. Vaingankar NV, Sylaidis P, Eagling V et al. Comparison of hydrocellular foam and calcium alginate in the healing and comfort of split-thickness skin-graft donor sites. J Wound Care 2001; 10: 289-91.
32. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibilit Tests for Bacteria That Grow Aerobically-Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
33. Morton JJ, Malone MH. Evaluation of vulnerary activity by an open wound procedure in rats. Arch Int Pharmacodyn Ther 1972; 196: 117-26.
34. Simonetti O, Cirioni O, Ghiselli R et al. RIP enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2205-11.
35. Church D, Elsayed S, Reid O et al. Burn wound infections. Clin Microbiol Rev 2006; 19: 403-34.
36. Dyer C, Roberts D. Thermal trauma. Nurs Clin N Am 1990; 25: 85-117.
37. Gibran NS, Heimbach DM. Current status of burn wound pathophysiology. Clin Plast Surg 2000; 27: 11-22.
38. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
39. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother 2001; 45: 999-1007.
40. Singh R, Ray P, Das A et al. Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms. J Antimicrob Chemother 2010; 65: 1955-8.
41. Raad I, Hanna H, Jiang Y et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51: 1656-60.
42. Trengove NJ, Stacey MC, MacAuley S et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7: 442-52.
43. Greenwald RA, Golub LM, Ramamurthy NS et al. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone 1998; 22: 33-8.
44. Konttinen YT, Halinen S, Hanemaaijer R et al. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren's syndrome. Matrix Biol 1998; 17: 335-47.
45. Reiss MJ, Han YP, Garcia E et al. Matrix metalloproteinase-9 delays wound healing in a murine wound model. Surgery 2010; 147: 295-302.
46. Widgerow AD. Chronic wound fluid-thinking outside the box. Wound Repair Regen 2011; 19: 287-91.
47. Pugin J, Widmer MC, Kossodo S et al. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999; 20: 458-64.
48. Elkington PT, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005; 142: 12-20.
49. Ricou B, Nicod L, Lacraz S et al. Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154: 346-52.
50. Hoffmann U, Bertsch T, Dvortsak E et al. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis 2006; 38: 867-72.
51. Lorente L, Martín MM, Labarta L et al. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care 2009 13: R158.
52. Gearing AJ, Beckett P, Christodoulou M et al. Processing of tumour necrosis factor-α precursor by metaloproteinases. Nature 1994; 370: 555-7.
53. Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1b by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1b processing. J Immunol 1998; 161: 3340-6.
54. Ito A, Mukaiyama A, Itoh Y et al. Degradation of interleukin 1b by matrix metalloproteinases. J Biol Chem 1996; 271: 14657-60.
55. Buck M, Houglum K, Chojkier M. Tumor necrosis factor-a inhibits collagen a1(I) gene expression and wound healing in a murine model of cachexia. Am J Pathol 1996; 149: 195-204.
56. Goldberg MT, Han YP, Yan C et al. TNF-a suppresses a-smooth muscle actin expression in human dermal fibroblasts: an implication for abnormal wound healing. J Invest Dermatol 2007; 127: 2645-55.
57. Lamparter S, Slight SH,Weber KT. Doxycycline and tissue repair in rats. J Lab Clin Med 2002; 139: 295-302.
58. Pasternak B, Rehn M, Andersen L et al. Doxycycline-coated sutures improve mechanical strength of intestinal anastomoses. Int J Colorectal Dis 2008; 23: 271-6.
59. Stechmiller J, Cowan L, Schultz G. The role of doxycycline as a matrix metalloproteinase inhibitor for the treatment of chronic wounds. Biol Res Nurs 2010; 11: 336-44.
60. Franco GC, Kajiya M, Nakanishi T et al. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligandinduced osteoclast differentiation in vitro and in vivo. Exp Cell Res 2011; 317: 1454-64.